Gomez-Gomez, E.; Moreno Sorribas, S.; Valero-Rosa, J.; Blanca, A.; Mesa, J.; Salguero, J.; Carrasco-Valiente, J.; López-Ruiz, D.; Anglada-Curado, F.J.
Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy? Diagnostics 2021, 11, 1335.
https://doi.org/10.3390/diagnostics11081335
AMA Style
Gomez-Gomez E, Moreno Sorribas S, Valero-Rosa J, Blanca A, Mesa J, Salguero J, Carrasco-Valiente J, López-Ruiz D, Anglada-Curado FJ.
Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy? Diagnostics. 2021; 11(8):1335.
https://doi.org/10.3390/diagnostics11081335
Chicago/Turabian Style
Gomez-Gomez, Enrique, Sara Moreno Sorribas, Jose Valero-Rosa, Ana Blanca, Juan Mesa, Joseba Salguero, Julia Carrasco-Valiente, Daniel López-Ruiz, and Francisco José Anglada-Curado.
2021. "Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?" Diagnostics 11, no. 8: 1335.
https://doi.org/10.3390/diagnostics11081335
APA Style
Gomez-Gomez, E., Moreno Sorribas, S., Valero-Rosa, J., Blanca, A., Mesa, J., Salguero, J., Carrasco-Valiente, J., López-Ruiz, D., & Anglada-Curado, F. J.
(2021). Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy? Diagnostics, 11(8), 1335.
https://doi.org/10.3390/diagnostics11081335
